HK1202589A1 - 用於 抑制劑治療之生物標記 - Google Patents

用於 抑制劑治療之生物標記

Info

Publication number
HK1202589A1
HK1202589A1 HK15102857.1A HK15102857A HK1202589A1 HK 1202589 A1 HK1202589 A1 HK 1202589A1 HK 15102857 A HK15102857 A HK 15102857A HK 1202589 A1 HK1202589 A1 HK 1202589A1
Authority
HK
Hong Kong
Prior art keywords
iap
biomarkers
inhibitor therapy
iap inhibitor
therapy
Prior art date
Application number
HK15102857.1A
Other languages
English (en)
Inventor
John Scott Cameron
Caroline Emery
Dale Porter
Douglas Robinson
Kavitha Venkatesan
Li Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HK1202589A1 publication Critical patent/HK1202589A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HK15102857.1A 2012-05-04 2015-03-20 用於 抑制劑治療之生物標記 HK1202589A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261642899P 2012-05-04 2012-05-04
PCT/US2013/039362 WO2013166344A1 (en) 2012-05-04 2013-05-03 Biomarkers for iap inhibitor therapy

Publications (1)

Publication Number Publication Date
HK1202589A1 true HK1202589A1 (zh) 2015-10-02

Family

ID=48407833

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15102857.1A HK1202589A1 (zh) 2012-05-04 2015-03-20 用於 抑制劑治療之生物標記

Country Status (20)

Country Link
US (1) US9353419B2 (zh)
EP (1) EP2844764B1 (zh)
JP (1) JP6513019B2 (zh)
KR (1) KR20150011822A (zh)
CN (1) CN104284988A (zh)
AU (1) AU2013256182A1 (zh)
BR (1) BR112014027413A2 (zh)
CA (1) CA2871995A1 (zh)
CL (1) CL2014002976A1 (zh)
ES (1) ES2593046T3 (zh)
HK (1) HK1202589A1 (zh)
IL (1) IL235315A0 (zh)
MA (1) MA37475A1 (zh)
MX (1) MX2014013429A (zh)
PH (1) PH12014502461A1 (zh)
RU (1) RU2014148779A (zh)
SG (1) SG11201406837TA (zh)
TN (1) TN2014000443A1 (zh)
TW (1) TW201347760A (zh)
WO (1) WO2013166344A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10441654B2 (en) 2014-01-24 2019-10-15 Children's Hospital Of Eastern Ontario Research Institute Inc. SMC combination therapy for the treatment of cancer
AU2015360291A1 (en) 2014-12-11 2017-07-13 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
AU2018358134A1 (en) 2017-11-01 2020-05-14 The Regents Of The University Of California Novel agents targeting inhibitor of apoptosis proteins

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5424186A (en) 1989-06-07 1995-06-13 Affymax Technologies N.V. Very large scale immobilized polymer synthesis
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
DE60324964D1 (de) 2002-07-15 2009-01-08 Univ Princeton Iap-bindende verbindungen
US7932382B2 (en) 2004-01-16 2011-04-26 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
WO2005069888A2 (en) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Smac peptidomimetics and the uses thereof
AU2005228950B2 (en) 2004-03-23 2012-02-02 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
KR20080083220A (ko) 2004-04-07 2008-09-16 노파르티스 아게 Ｉａｐ 억제제
KR100984459B1 (ko) 2004-07-02 2010-09-29 제넨테크, 인크. Ｉａｐ의 억제제
US7674787B2 (en) 2004-07-09 2010-03-09 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
EA200700225A1 (ru) 2004-07-12 2008-02-28 Айдан Фармасьютикалз, Инк. Аналоги тетрапептида
AU2005274937B2 (en) 2004-07-15 2011-08-18 Medivir Ab IAP binding compounds
JP5007235B2 (ja) 2004-12-20 2012-08-22 ジェネンテック， インコーポレイテッド Ｉａｐのピロリジンインヒビター
CN101365806B (zh) * 2005-12-01 2016-11-16 医学预后研究所 用于鉴定治疗反应的生物标记的方法和装置及其预测疗效的用途
BRPI0717411A2 (pt) 2006-10-19 2013-11-12 Novartis Ag Uso de inibidores de iap
CN101529254A (zh) * 2006-10-19 2009-09-09 诺瓦提斯公司 有机化合物
US8907092B2 (en) 2007-04-30 2014-12-09 Genentech, Inc. Inhibitors of IAP
JP2012516149A (ja) * 2009-01-29 2012-07-19 オットー−フォン−ゲーリケ−ウニヴェルジテート マグデブルク Ｉａｐアンタゴニストに対するヒトまたは非ヒト動物細胞の感受性を決定する方法
EP3722810A3 (en) * 2009-02-11 2021-01-13 Caris MPI, Inc. Molecular profiling of tumors
JP2013505446A (ja) * 2009-09-18 2013-02-14 ノバルティス アーゲー Ｉａｐ阻害剤化合物のためのバイオマーカー
CN101956014B (zh) * 2010-09-30 2014-05-28 中山大学 一种用于鼻咽癌早期诊断的外周血7个基因标志物的检测试剂盒

Also Published As

Publication number Publication date
MA37475A1 (fr) 2016-05-31
TW201347760A (zh) 2013-12-01
US9353419B2 (en) 2016-05-31
SG11201406837TA (en) 2014-11-27
JP2015523056A (ja) 2015-08-13
AU2013256182A1 (en) 2014-11-13
EP2844764B1 (en) 2016-06-22
US20150105434A1 (en) 2015-04-16
MX2014013429A (es) 2014-12-08
EP2844764A1 (en) 2015-03-11
WO2013166344A1 (en) 2013-11-07
CL2014002976A1 (es) 2015-02-13
PH12014502461A1 (en) 2014-12-22
IL235315A0 (en) 2014-12-31
JP6513019B2 (ja) 2019-05-15
ES2593046T3 (es) 2016-12-05
BR112014027413A2 (pt) 2017-06-27
TN2014000443A1 (en) 2016-03-30
CN104284988A (zh) 2015-01-14
RU2014148779A (ru) 2016-06-27
KR20150011822A (ko) 2015-02-02
CA2871995A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
HK1211921A1 (zh) 抑制劑化合物
GB201213567D0 (en) Biomarkers
IL229336A (en) Biomarkers for hedgehog protein inhibitor-related therapy
GB201211982D0 (en) Biomarker
HK1203949A1 (zh) 抑制劑
HK1209422A1 (zh) 抑制劑
EP2828282A4 (en) BIOMARKERS
GB201210565D0 (en) Biomarkers
HK1202589A1 (zh) 用於 抑制劑治療之生物標記
GB201209802D0 (en) Biomarker
GB201202944D0 (en) Biomarker
GB201211019D0 (en) Inhibitor compounds
GB201204391D0 (en) Biomarker
GB201200507D0 (en) Biomarker
ZA201407646B (en) Biomarkers for iap inhibitor therapy
GB201216562D0 (en) Biomarker
GB201214806D0 (en) Biomarker
GB201211229D0 (en) Biomarker
GB201209785D0 (en) Biomarker

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20200506